AccessibilityHelp

Most Active Stocks Daily Stock Gainers Daily Stock Losers

Most Active Stocks Daily Stock Gainers Daily Stock Losers

George Budwell, PhD

TMFGBudwell

George Budwell, PhD, is a contributing Motley Fool biotechnology and technology analyst covering disruptive innovators in healthcare, defense, and artificial intelligence. He also writes on portfolio theory, dividend stocks, and value investing. Prior to The Motley Fool, George was a freelance medical and science writer and a consultant for several life sciences hedge funds. Earlier in his career, he was an evolutionary biologist and completed postdoctoral fellowships at Kyoto University and Illinois State University. He holds a doctorate in evolutionary biology from Tulane University and a bachelor’s degree from Loyola University.

Articles by George Budwell, PhD — Page 151

GlaxoSmithKline vs. Sanofi: Which Is The Better Dividend Stock?

Nov 20, 2014 by George Budwell, PhD

GlaxoSmithKline vs. Sanofi: Which Is The Better Dividend Stock?

Shares of healthcare giants GlaxoSmithKline and Sanofi have fallen hard this year, resulting in unusually high dividend yields for these two companies. Here is a look at which company offers the better opportunity for income investors moving forward.

Why Top Dividend Stock Johnson & Johnson Could Plunge in 2015

Nov 17, 2014 by George Budwell, PhD

Why Top Dividend Stock Johnson & Johnson Could Plunge in 2015

Johnson & Johnson has had a great year largely because of its hepatitis C drug Olysio. This top dividend stock, though, might reverse course in 2015. Here's why.

AbbVie Inc. vs. Pfizer Inc.: Which Is the Better Dividend Stock?

Nov 16, 2014 by George Budwell, PhD

AbbVie Inc. vs. Pfizer Inc.: Which Is the Better Dividend Stock?

AbbVie and Pfizer are top healthcare stocks offering sector-beating dividend yields. Which company is the better long-term buy for income investors?

5 Things Actavis plc's Management Wants You to Know

Nov 12, 2014 by George Budwell, PhD

5 Things Actavis plc's Management Wants You to Know

Specialty and generic drugmaker Actavis plc reported another monster quarter last week. Here are five things management wants investors to know going forward.

Bill Ackman vs. Allergan, Inc.: Who Will Win the War of Words?

Nov 11, 2014 by George Budwell, PhD

Bill Ackman vs. Allergan, Inc.: Who Will Win the War of Words?

Valeant Pharmaceuticals' takeover bid for Allergan has turned hostile in more ways than one.

Can Arena Pharmaceuticals Inc. Overcome Belviq's Slow Launch?

Nov 11, 2014 by George Budwell, PhD

Can Arena Pharmaceuticals Inc. Overcome Belviq's Slow Launch?

Arena Pharmaceuticals stock has fallen hard after a slower than expected launch of its fat-fighting pill Belviq. During its third-quarter conference call, though, management gave three reasons investors should be optimistic moving forward.

Is This MannKind Corporation's Worst Nightmare?

Nov 10, 2014 by George Budwell, PhD

Is This MannKind Corporation's Worst Nightmare?

MannKind's long-awaited inhaled insulin product is nearing a commercial launch. The drug may be in for a bumpier ride than most expect, however. Here's why.

Why AbbVie Inc.'s Game-Changing New Drug Could Be a Serious Threat to Gilead Sciences Inc.

Nov 7, 2014 by George Budwell, PhD

Why AbbVie Inc.'s Game-Changing New Drug Could Be a Serious Threat to Gilead Sciences Inc.

AbbVie isn't conceding defeat in the next-generation hepatitis C drug race. Here's why.

Actavis plc's Strong Third-Quarter Earnings Reflect Its Acquisition Bonanza

Nov 5, 2014 by George Budwell, PhD

Actavis plc's Strong Third-Quarter Earnings Reflect Its Acquisition Bonanza

Actavis posted third-quarter earnings this morning. Here's what you need to know.

Key Takeaways From Teva Pharmaceutical Industries Ltd.'s Third-Quarter Earnings

Nov 4, 2014 by George Budwell, PhD

Key Takeaways From Teva Pharmaceutical Industries Ltd.'s Third-Quarter Earnings

Specialty and generic drugmaker Teva reported third-quarter earnings last week. Here's what you need to know.

5 Things Bristol-Myers Squibb Co.'s Management Wants You to Know

Oct 30, 2014 by George Budwell, PhD

5 Things Bristol-Myers Squibb Co.'s Management Wants You to Know

Bristol-Myers Squibb reported third-quarter earnings last week. Here are five things management wants investors to know.

5 Things GlaxoSmithKline plc Stock's Management Wants You to Know

Oct 30, 2014 by George Budwell, PhD

5 Things GlaxoSmithKline plc Stock's Management Wants You to Know

GlaxoSmithKline held its third-quarter conference call last week. Here's what the company's management wants you to know.

Will Marijuana-Based Pharmaceuticals Make Drugs More Affordable?

Oct 27, 2014 by George Budwell, PhD

Will Marijuana-Based Pharmaceuticals Make Drugs More Affordable?

Marijuana-based pharmaceuticals are becoming a reality. Will these "natural" products come with the added benefit of lower price tags compared to their man-made counterparts?

Why Sarepta Therapeutics Inc Stock Is Crashing Today

Oct 27, 2014 by George Budwell, PhD

Why Sarepta Therapeutics Inc Stock Is Crashing Today

Shares of clinical-stage biotech Sarepta Therapeutics fell by nearly 40% this morning. Here's why.

Why I Won't Buy Ebola Stocks

Oct 27, 2014 by George Budwell, PhD

Why I Won't Buy Ebola Stocks

The share prices of companies leading the fight against Ebola have been soaring lately. Is this investor enthusiasm justified?

Bristol-Myers Squibb Co's Third-Quarter Earnings Beat the Street

Oct 24, 2014 by George Budwell, PhD

Bristol-Myers Squibb Co's Third-Quarter Earnings Beat the Street

Bristol-Myers Squibb reported third-quarter earnings this morning. Here's what you need to know.

3 Beaten Down Biotech Stocks to Buy Now

Oct 23, 2014 by George Budwell, PhD

3 Beaten Down Biotech Stocks to Buy Now

The share prices of Dynavax Technologies, CellDex Therapeutics, and Clovis Oncology have all plunged this year. Here is why I think these beaten down biotechs are now compelling buys.

Key Takeaways From GlaxoSmithKline's Third-Quarter Earnings

Oct 22, 2014 by George Budwell, PhD

Key Takeaways From GlaxoSmithKline's Third-Quarter Earnings

British Pharma GlaxoSmithKline reported third-quarter earnings this morning. Here's what you need to know.

Is Johnson & Johnson's Worst Nightmare Becoming Reality?

Oct 22, 2014 by George Budwell, PhD

Is Johnson & Johnson's Worst Nightmare Becoming Reality?

Johnson & Johnson has become a growth story on the back of strong pharmaceutical sales over the past two quarters. This trend looks like it is about to change with the approval of a rival's game-changing drug.

3 Stocks I'll Buy if the Market Crashes

Oct 20, 2014 by George Budwell, PhD

3 Stocks I'll Buy if the Market Crashes

The market could be in the midst of a major downturn. Here are three stocks to consider buying if the market does crash.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services